Quanterix Co. Forecasted to Post Q1 2025 Earnings of ($0.22) Per Share (NASDAQ:QTRX)

Quanterix Co. (NASDAQ:QTRX) – Investment analysts at Leerink Partnrs issued their Q1 2025 earnings per share (EPS) estimates for shares of Quanterix in a research note issued on Wednesday, May 8th. Leerink Partnrs analyst P. Souda forecasts that the company will post earnings per share of ($0.22) for the quarter. The consensus estimate for Quanterix’s current full-year earnings is ($1.04) per share. Leerink Partnrs also issued estimates for Quanterix’s Q2 2025 earnings at ($0.22) EPS, Q3 2025 earnings at ($0.23) EPS and Q4 2025 earnings at ($0.23) EPS.

Several other research firms have also commented on QTRX. Scotiabank lifted their price target on Quanterix from $30.00 to $32.00 and gave the stock a “sector outperform” rating in a research report on Monday, March 4th. Canaccord Genuity Group dropped their target price on Quanterix from $32.00 to $25.00 and set a “buy” rating for the company in a report on Monday, April 29th. Five analysts have rated the stock with a buy rating and one has assigned a strong buy rating to the stock. According to data from MarketBeat.com, Quanterix currently has a consensus rating of “Buy” and a consensus target price of $30.60.

Quanterix Stock Up 3.7 %

Shares of NASDAQ:QTRX opened at $17.12 on Friday. The firm has a fifty day simple moving average of $21.23 and a two-hundred day simple moving average of $23.05. The stock has a market capitalization of $654.79 million, a P/E ratio of -19.91 and a beta of 1.41. Quanterix has a 52 week low of $14.26 and a 52 week high of $29.70.

Quanterix (NASDAQ:QTRX) last posted its earnings results on Thursday, February 29th. The company reported ($0.33) EPS for the quarter, missing analysts’ consensus estimates of ($0.28) by ($0.05). Quanterix had a negative net margin of 26.42% and a negative return on equity of 9.15%. The firm had revenue of $31.55 million for the quarter, compared to the consensus estimate of $27.92 million.

Institutional Inflows and Outflows

Several hedge funds and other institutional investors have recently bought and sold shares of the company. Robeco Institutional Asset Management B.V. bought a new position in shares of Quanterix during the 3rd quarter worth $67,000. AJOVista LLC bought a new position in Quanterix during the 4th quarter worth about $81,000. DekaBank Deutsche Girozentrale purchased a new position in Quanterix during the 3rd quarter valued at about $125,000. Picton Mahoney Asset Management bought a new stake in shares of Quanterix in the 4th quarter valued at about $139,000. Finally, Zurcher Kantonalbank Zurich Cantonalbank lifted its position in shares of Quanterix by 56.5% in the 3rd quarter. Zurcher Kantonalbank Zurich Cantonalbank now owns 7,683 shares of the company’s stock worth $209,000 after purchasing an additional 2,775 shares during the period. Institutional investors own 86.48% of the company’s stock.

Insider Buying and Selling

In other news, Director Laurie J. Olson sold 1,500 shares of the company’s stock in a transaction dated Wednesday, February 14th. The shares were sold at an average price of $24.35, for a total value of $36,525.00. Following the transaction, the director now directly owns 15,238 shares in the company, valued at $371,045.30. The transaction was disclosed in a document filed with the SEC, which is available at the SEC website. 6.90% of the stock is owned by corporate insiders.

About Quanterix

Quanterix Corporation, a life sciences company, engages in development and marketing of digital immunoassay platforms that advances precision health for life sciences research and diagnostics in North America, Europe, the Middle East, Africa, and the Asia Pacific regions. The company offers HD-X instrument, a protein detection platform; and SR-X instrument that enables researchers to apply Simoa detection in an expanded range of applications.